These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 33500629)

  • 1. Gastric Cancer Harboring an
    Ding K; Chen X; Li Y; Li W; Ye Y; He T; Wang W; Zhang H
    Onco Targets Ther; 2021; 14():545-550. PubMed ID: 33500629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to Pyrotinib in a Patient with Metastatic Bladder Urothelial Carcinoma Harboring HER2 V842I Mutation: A Case Report.
    Li S; Liu Q; Liu M; Liu T
    Cancer Manag Res; 2022; 14():2927-2932. PubMed ID: 36200096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Partial Response to Pyrotinib Plus Capecitabine in an Advanced Breast Cancer Patient with
    Qu Y; Liu Y; Ding K; Li Y; Hong X; Zhang H
    Onco Targets Ther; 2021; 14():1581-1588. PubMed ID: 33688205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Pyrotinib in a Heavily Pretreated Patient with Lung Adenocarcinoma Harboring HER2 Amplification and Exon 20 Insertions: A Case Report.
    Shan J; Ruan J; Tan Y; Yan L; Chen S; Du M; Wang L
    Onco Targets Ther; 2020; 13():9849-9856. PubMed ID: 33061462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case Report: Durable Clinical Response to Third-Line Pyrotinib After Resistance to Trastuzumab in a Gastric Cancer Patient.
    Wu J; Li L; Qin J; Yan Z; Chen S; Jin T; Xu J
    Front Oncol; 2021; 11():780577. PubMed ID: 35155188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice].
    Song GH; Li HP; DI LJ; Yan Y; Jiang HF; Xu L; Wan DG; Li Y; Wang MP; Xiao Y; Zhang RY; Ran R; Wang H
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):254-260. PubMed ID: 32306007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Durable Effect of Pyrotinib Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric Cancer With Brain Metastases: A Case Report and Literature Review.
    Wang X; Zeng Y; Zhang J; Huang M; Yin B
    Front Oncol; 2022; 12():940263. PubMed ID: 35875121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Pyrotinib in HER2-Overexpressing Salivary Duct Carcinoma With Lung Metastasis: A Case Report.
    Yang ZY; Huang JH; Chen B; Xu CW; Lei L; Wang XJ; Fang MY
    Front Oncol; 2020; 10():559057. PubMed ID: 33123470
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
    Ma F; Li Q; Chen S; Zhu W; Fan Y; Wang J; Luo Y; Xing P; Lan B; Li M; Yi Z; Cai R; Yuan P; Zhang P; Li Q; Xu B
    J Clin Oncol; 2017 Sep; 35(27):3105-3112. PubMed ID: 28498781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial.
    Wang C; Lin Y; Zhou Y; Mao F; Zhu H; Guan J; Zhang X; Shen S; Huang X; Chen C; Yao R; Zhao J; Sun Q
    BMC Cancer; 2020 Jul; 20(1):653. PubMed ID: 32660609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.
    Xu B; Yan M; Ma F; Hu X; Feng J; Ouyang Q; Tong Z; Li H; Zhang Q; Sun T; Wang X; Yin Y; Cheng Y; Li W; Gu Y; Chen Q; Liu J; Cheng J; Geng C; Qin S; Wang S; Lu J; Shen K; Liu Q; Wang X; Wang H; Luo T; Yang J; Wu Y; Yu Z; Zhu X; Chen C; Zou J;
    Lancet Oncol; 2021 Mar; 22(3):351-360. PubMed ID: 33581774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyrotinib treatment on HER2-positive gastric cancer cells promotes the released exosomes to enhance endothelial cell progression, which can be counteracted by apatinib.
    Gao Z; Song C; Li G; Lin H; Lian X; Zhang N; Cao B
    Onco Targets Ther; 2019; 12():2777-2787. PubMed ID: 31114227
    [No Abstract]   [Full Text] [Related]  

  • 13. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.
    Wang Y; Jiang T; Qin Z; Jiang J; Wang Q; Yang S; Rivard C; Gao G; Ng TL; Tu MM; Yu H; Ji H; Zhou C; Ren S; Zhang J; Bunn P; Doebele RC; Camidge DR; Hirsch FR
    Ann Oncol; 2019 Mar; 30(3):447-455. PubMed ID: 30596880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.
    Ma F; Ouyang Q; Li W; Jiang Z; Tong Z; Liu Y; Li H; Yu S; Feng J; Wang S; Hu X; Zou J; Zhu X; Xu B
    J Clin Oncol; 2019 Oct; 37(29):2610-2619. PubMed ID: 31430226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remarkable Response of
    Li HS; Yang LL; Zhang MY; Cheng K; Chen Y; Liu JY
    Front Oncol; 2020; 10():548867. PubMed ID: 33194604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes.
    Nishimura T; Iwasa S; Nagashima K; Okita N; Takashima A; Honma Y; Kato K; Hamaguchi T; Yamada Y; Shimada Y; Boku N
    Gastric Cancer; 2017 Jul; 20(4):655-662. PubMed ID: 27858180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical use of trastuzumab combined with different chemotherapy regimens in multi-line treatment of advanced human epidermal growth factor receptor 2-positive gastric cancer: A case report.
    Chen ZL; Zhao A; Li P; Zhang M; Yang J; Zhang L; Zhao X; Yang J; Wang L
    Oncol Lett; 2018 Oct; 16(4):4614-4620. PubMed ID: 30214596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib.
    Zhang X; Lv J; Wu Y; Qin N; Ma L; Li X; Nong J; Zhang H; Zhang Q; Yang X; Shi H; Wang J; Zhang S
    Front Oncol; 2020; 10():1162. PubMed ID: 32850330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial.
    Li Q; Guan X; Chen S; Yi Z; Lan B; Xing P; Fan Y; Wang J; Luo Y; Yuan P; Cai R; Zhang P; Li Q; Zhong D; Zhang Y; Zou J; Zhu X; Ma F; Xu B
    Clin Cancer Res; 2019 Sep; 25(17):5212-5220. PubMed ID: 31138588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastatic brain tumors respond favorably to pyrotinib in a HER2-positive breast cancer following failure using trastuzumab.
    Yao JH; Xie ZY; Li M; Zhang ML; Ci HF; Yang Y
    Am J Transl Res; 2020; 12(9):5874-5881. PubMed ID: 33042466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.